8 h. ago Rakovina Therapeutics Granted DTC Eligibility to Expand U.S. Investor Access

VANCOUVER, British Columbia, July 15, 2025 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing next-generation cancer therapies through artificial intelligence (AI)-powered drug discovery, is pleased to announce that its shares are now eligible for electronic clearing and settlement through The Depository Trust Company (DTC). DTC […]

Other

4 d. ago Rakovina Therapeutics Congratulates Partner – Variational AI for Winning LifeSciencesBC’s 2025 Emerging Biotech Company of the Year Award

Award Recognition underscores the importance of AI-driven drug discovery VANCOUVER, British Columbia, July 11, 2025 (GLOBE NEWSWIRE) —  Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing next-generation cancer therapies through AI-powered drug discovery proudly congratulates partner, Variational AI, on being honored as the 2025 Emerging Company of the Year […]

Economics

5 d. ago Rakovina Therapeutics Highlights Strength of Scientific Advisory Board Driving Innovation in AI

VANCOUVER, British Columbia, July 10, 2025 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing next-generation cancer therapies through artificial intelligence (AI)-powered drug discovery, is pleased to highlight the strength and scientific leadership of its established Scientific Advisory Board (SAB). Rakovina’s SAB is composed of internationally […]

Other

2 w. ago Rakovina Therapeutics Announces Intention to Amend Debentures and Warrants

VANCOUVER, British Columbia, June 30, 2025 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. (TSXV: RKV) (the “Company”) announces that it will apply to the TSX Venture Exchange (the “Exchange”) to amend the terms of certain outstanding warrants and convertible debentures of the Company, as further described herein. Convertible Debenture Amendments The Company intends to file an application […]

Other

2 w. ago Rakovina Therapeutics Highlights Strong H1 Progress and Unveils Strategic Priorities for H2 2025

VANCOUVER, British Columbia, June 30, 2025 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing next-generation cancer therapies through artificial intelligence (AI)-powered drug discovery, today shared a summary of its H1 2025 accomplishments and provided an outline of its strategic objectives for H2 2025 – against […]

Other

2 w. ago Rakovina Therapeutics Announces Results from 2025 Annual General Meeting

VANCOUVER, British Columbia, June 25, 2025 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) (“Rakovina” or the “Company”), a biopharmaceutical company advancing next-generation cancer therapies through artificial intelligence (AI)-powered drug discovery is pleased to announce the results of voting at its 2025 annual general meeting of shareholders held on June 25, 2025, in […]

Other

3 w. ago Rakovina Therapeutics Announces Share Consolidation Effective Date

VANCOUVER, British Columbia, June 20, 2025 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE:7JO) (“Rakovina” or the “Company”) is pleased to announce that the effective date for the previously announced share consolidation (the “Consolidation”) will be June 24, 2025. As outlined in the Company’s news release dated May 15, 2025, the Consolidation will be […]

Other